EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Backed by ASCO data Arcus guns for phase 3
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
